- In October 2024, Chugai Pharmaceutical Co., Ltd. announced that Verastem Oncology presented updated RAMP 201 data on the RAF/MEK clamp, Avutometinib, for recurrent low-grade serous ovarian cancer at the IGCS 2024 Annual Meeting. Developed by Chugai, the clinical development of Avutometinib by Verastem enhances Chugai’s oncology portfolio and strengthens its presence in cancer therapeutics
- In June 2024, The FDA granted approval for Tepylute (formerly SH-105), a ready-to-dilute formulation designed to treat adenocarcinoma of the breast and ovary. This approval will significantly enhance the company's portfolio, opening new market opportunities and potentially expanding its presence in oncology therapeutics.
- In February 2024, BioNTech SE and Autolus Therapeutics plc formed a strategic partnership to advance their autologous CAR-T programs toward commercialization, subject to regulatory approvals. This collaboration strengthens both companies’ oncology pipelines and accelerates their entry into the CAR-T therapy market
- In February 2024, AbbVie successfully completed its acquisition of ImmunoGen, making ImmunoGen a part of AbbVie. This acquisition strengthens AbbVie’s oncology portfolio and accelerates its research and development capabilities in targeted cancer therapies
- In October 2023, BioNTech SE shared follow-up data from its Phase 1/2 trial (NCT04503278; 2019-004323-20) on the safety and efficacy of its Claudin-6-directed CAR-T therapy, BNT211, for CLDN6-positive refractory/relapsed solid tumors. This progress boosts BioNTech’s CAR-T pipeline and advances its position in the immuno-oncology market
